生物医药系列产品
数据
资源
版本对比
免费注册
预约演示
免费注册
Ortho Dermatologics Announces Statistically Significant Topline Results From Second Pivotal Phase 3 Clinical Trial Evaluating
IDP-126
Gel In
Acne Vulgaris
2021-04-22
·
BioSpace
First in Class
All Three Co-Primary Endpoints Were Achieved LAVAL, QC, April 22, 2021 /PRNewswire/ --
Bausch Health Companies Inc.
(NYSE/TSX: BHC) ("Bausch Health") and its dermatology business,
Ortho Dermatologics
, one of the largest prescription dermatology health care businesses, today announced statistically significant topline results from a second pivotal Phase 3 clinical trial evaluating its investigational medicine
IDP-126
, a combination retinoid, anti-bacterial and antibiotic topical, to treat
acne vulgaris
in patients nine years of age and older. If approved,
IDP-126
would be the first-in-class with this triple combination.
Acne
is the most common skin problem in the United States, affecting up to 50 million Americans.1,2 The second Phase 3 study confirmed the findings of the first Phase 3 study, which met all of its co-primary endpoints. This second Phase 3 study achieved all three co-primary endpoints at week 12 with statistical significance, including: Absolute change from baseline in inflammatory lesion count [p-value<0.001] Absolute change from baseline in non-inflammatory lesion count [p-value<0.001] Percentage of patients who achieved treatment success (defined as a two-grade reduction from baseline and 'clear' or 'almost clear' skin in Evaluator's Global Severity Score (EGSS)) (p=0.001) Treatment success was 50.5% and 20.5% for
IDP-126
and its vehicle, respectively. The data also demonstrated a benefit for patients as early as two weeks. "The results from this pivotal Phase 3 trial indicate a strong safety, tolerability and efficacy pro
IDP-126
and reinforce its potential as a first-in-class treatment option for millions of patients struggling with
acne
," said Scott Hirsch, president, Ortho Dermatologics, and senior vice president and chief strategy officer, Bausch Health. "Following the results of a comparative bridging study, we hope to submit a New Drug Application for
IDP-126
to the U.S. Food and Drug Administration in the second half of 2022." "The positive results of this second Phase 3 study for
IDP-126
are consistent with the strong, conclusive results seen in the findings from the first Phase 3 study. If approved,
IDP-126
will deliver a triple-combination retinoid therapy – three active ingredients into one product – which could have a meaningful impact for my patients suffering from
acne
," said Linda Stein Gold, M.D., director, Dermatology Clinical
Research
, Henry Ford Health System. Summary of Second Phase 3 Study Results The multicenter, randomized, double-blind, vehicle-controlled, 12-week study was designed to assess the safety, tolerability and efficacy of
IDP-126
Gel in comparison to
IDP-126
vehicle gel. The data was based on results from 193 participants nine years of age and older who were randomized to either receive treatment with
IDP-126
gel applied topically to the face once daily for 12 weeks or administration of placebo (
IDP-126
vehicle gel) applied topically to the face once daily for 12 weeks. The study was conducted at 13 locations in the United States. Treatment emergent adverse events (TEAE) reported in >2% of patients included
application site pain
, dryness, irritation,
erythema
, exfoliation and xerosis. About
Ortho Dermatologics
Ortho Dermatologics
is one of the largest dermatology businesses dedicated to helping patients in the treatment of a range of therapeutic areas, including
psoriasis
,
actinic keratosis
,
acne
,
atopic dermatitis
and other
dermatoses
. The
Ortho Dermatologics
portfolio is further complemented by Solta Medical, the maker of Fraxel®,
Thermage
®, Clear + Brilliant® and Vaser® ultrasonic assisted liposuction for aesthetic applications. More information can be found at . About
Bausch Health
Bausch Health Companies Inc.
(NYSE/TSX: BHC) is a global company whose mission is to improve people's lives with our health care products. We develop, manufacture and market a range of pharmaceutical, medical device and over-the-counter products, primarily in the therapeutic areas of eye health, gastroenterology and dermatology. We are delivering on our commitments as we build an innovative company dedicated to advancing global health. More information can be found at . Forward-looking Statements This news release may contain forward-looking statements, which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, the risks and uncertainties discussed in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. They also include, but are not limited to, risks and uncertainties caused by or relating to the evolving
COVID-19 pandemic
, and the fear of that pandemic and its potential effects, the severity, duration and future impact of which are highly uncertain and cannot be predicted, and which may have a material adverse impact on
Bausch Health
, including but not limited to its project development timelines, and costs (which may increase). Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof.
Bausch Health
undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this news release or to reflect actual outcomes, unless required by law. References
American Academy of Dermatology
. (2020). Skin conditions by the numbers. Retrieved from . Accessed April 20, 2021. Mayo Clinic. (2020).
Acne
. Retrieved from . Accessed April 20, 2021. ®/TM are trademarks of
Ortho Dermatologics
' affiliated entities. © 2021
Ortho Dermatologics
' affiliated entities. ORD.0079.USA.21 View original content to download multimedia:
SOURCE Bausch Health Companies Inc. Company
Codes: NYSE:BHC, Toronto:BHC
机构
Ortho Dermatologics
Research Research Ltd.
American Academy of Dermatology
[+2]
适应症
寻常痤疮
疼痛
红斑
[+5]
靶点
-
药物
阿达帕林/过氧苯甲酰/克林霉素磷酸酯
标准版
¥
16800
元/账号/年
新药情报库 | 省钱又好用!
立即使用
来和芽仔聊天吧
热门报告
特应性皮炎深度解析:药物开发、专利分析与风险评估
智慧芽生物医药
2024年7月全球首批及特殊审评药物报告
智慧芽生物医药
GPRC5D靶点专利调研报告
智慧芽生物医药
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台,助您全方位提升您的研发与决策效率。
开始免费试用
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台,以API或者数据包形式对外开放,助您更加充分利用智慧芽新药情报信息。
试用数据服务